Medicare Reimbursement 101
For Medical Device Reps

Who actually pays the bill?

Roughly half of U.S. hospital revenue comes from Medicare. Whatever Medicare pays, commercial payers largely follow. That makes the Centers for Medicare & Medicaid Services (CMS) the de facto pricing authority for most devices.

• CMS publishes annual fee schedules: IPPS (inpatient), OPPS (outpatient), ASC, and Physician Fee Schedule.
• Commercial payers anchor to Medicare rates plus a multiplier (often 120–180%).
• Medicaid rates vary by state and are typically the lowest.
• Self-pay and bundled-payment contracts are growing — and often more sensitive to device cost.

The four codes every rep should know

• ICD-10: diagnosis. Tells the payer why the patient was treated.
• CPT: physician procedure code. Tells the payer what the surgeon did.
• HCPCS Level II: device, supply, and DME codes (e.g. C-codes for outpatient devices, L-codes for orthotics).
• MS-DRG: the inpatient bundle. Determines a single fixed payment for the entire admission.

Reps don't code claims, but the difference between DRG 216 and DRG 220 can be tens of thousands of dollars per case. Knowing the relevant DRG family for your procedure tells you whether the hospital will profit, break even, or lose money on each implant.

Site of service: same procedure, different math

A total knee performed in a hospital outpatient department, an ASC, and an inpatient setting all pay differently. The rep who can articulate the cost-per-case math at each site of service controls the conversation.

• Inpatient (IPPS): bundled DRG payment — implant cost comes straight out of the hospital margin.
• Hospital outpatient (OPPS): paid by APC. Pass-through codes can isolate the device cost for several years after launch.
• ASC: paid on the ASC fee schedule, typically ~60% of HOPD. Implant cost matters even more here.
• Office: paid on the Physician Fee Schedule. The physician owns both the procedure margin and the supply cost.

NTAP, TPT, and how launches stay alive

When a new device costs more than the existing DRG can absorb, CMS has two main relief valves:

• NTAP (New Technology Add-on Payment): pays inpatient hospitals up to 65% of the device cost on top of the DRG, typically for 2–3 years.
• TPT (Transitional Pass-Through, “C-codes”): isolates outpatient device cost from the APC bundle for ~3 years.
• Both require a CMS application, FDA clearance/approval, and evidence of substantial clinical improvement.
• When a launch has NTAP/TPT, lead with it. When it loses NTAP/TPT, expect adoption resistance and prep an economic story.

Building the economic story

Reimbursement-fluent reps walk into a VAC with a one-page economic model: payer mix, expected case volume, current vs. proposed device cost, downstream savings (length-of-stay, complications, OR time), and net margin impact per case.

• Pull the hospital's payer mix from your manufacturer's health-economics team.
• Use published HCUP or PINC AI data when internal data isn't available.
• Model conservative assumptions — credibility beats aggressive ROI.
• Always show two scenarios: status quo vs. with your device.

How MedSales Network helps

Reps with reimbursement fluency win launches and capital deals others can't touch. Surface that experience on your profile so hiring teams can find you.